BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duchow A, Paul F, Bellmann-strobl J. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. Expert Opinion on Biological Therapy 2020;20:1061-72. [DOI: 10.1080/14712598.2020.1749259] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Schindler P, Aktas O, Ringelstein M, Wildemann B, Jarius S, Paul F, Ruprecht K. Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review. Expert Rev Clin Immunol 2023;19:71-91. [PMID: 36378751 DOI: 10.1080/1744666X.2023.2148657] [Reference Citation Analysis]
2 Gholizadeh S, Exuzides A, Lewis KE, Palmer C, Waltz M, Rose JW, Jolley AM, Behne JM, Behne MK, Blaschke TF, Smith TJ, Sinnott J, Cook LJ, Yeaman MR, Aguerre I, Amezcua L, Chitnis T, Lewis JC, Engel C, Han MH, Klawiter EC, Kocsik A, Kruse-hoyer M, Levine L, Levy M, Marcille M, Mealy MA, Moore S, Mullin DS, Nelson KE, Onomichi KB, Planchon SM, Pruitt A, Repovic P, Riley CS, Rimler Z, Russo AW, Ocampo CT, Tomczak AJ, The Guthy-Jackson Charitable Foundation CIRCLES Study Group. Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort. J Neurol 2022. [DOI: 10.1007/s00415-022-11529-6] [Reference Citation Analysis]
3 Jiao L, Guo S. Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.966766] [Reference Citation Analysis]
4 Zrzavy T, Leutmezer F, Rommer P, Bsteh G, Kornek B, Berger T, Prayer D, Thurnher M, Haider L. Imaging features to distinguish AQP4-positive NMOSD and MS at disease onset: A retrospective analysis in a single-center cohort. Eur J Radiol 2022;146:110063. [PMID: 34922119 DOI: 10.1016/j.ejrad.2021.110063] [Reference Citation Analysis]
5 Cabal-Herrera AM, Mateen FJ. Randomized Controlled Trials for Neuromyelitis Optica Spectrum Disorder: A Review of Trial Architecture. Neurologist 2021;27:14-20. [PMID: 34855669 DOI: 10.1097/NRL.0000000000000376] [Reference Citation Analysis]
6 Li R, Wang J, Li C, Liu X, Chu M, Chang Y, Wang Y, Wang X, Yu B, Ling L, Yang H, Yang H, Hu X, Qiu W. Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone. J Neuroimmunol 2021;356:577604. [PMID: 33992860 DOI: 10.1016/j.jneuroim.2021.577604] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Duchow A, Bellmann-strobl J. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegenerative Disease Management 2021;11:49-59. [DOI: 10.2217/nmt-2020-0046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
8 Sharma J, Bhatti MT, Danesh-Meyer HV. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review. Clin Exp Ophthalmol 2021;49:186-202. [PMID: 33426799 DOI: 10.1111/ceo.13863] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 2020;16:601-17. [PMID: 33005040 DOI: 10.1038/s41582-020-0400-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 23.3] [Reference Citation Analysis]
10 Asseyer S, Cooper G, Paul F. Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. Front Neurol 2020;11:778. [PMID: 33473247 DOI: 10.3389/fneur.2020.00778] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
11 Giglhuber K, Berthele A. Eculizumab in the treatment of neuromyelitis optica spectrum disorder. Immunotherapy 2020;12:1053-66. [PMID: 32772617 DOI: 10.2217/imt-2020-0163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Kuchling J, Paul F. Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Front Neurol 2020;11:450. [PMID: 32625158 DOI: 10.3389/fneur.2020.00450] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]